Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Q3 FY26 Earnings Presentation
16 slides from Poly Medicure's earnings presentation, Feb 5, 2026
Slide 1: Submission of Investor's Presentation cover letter
Poly Medicure Limited Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate, ' IPOLYMED Phase-Ill, New Delhi - 110 020 (INDIA) T: +91-11- 33550700, 47317000 E: info@polymedicure.com W. polymedicure.com CIN: L 40300DL1995PLC066923 'f Date: 05 th February 2026 Scrip Code: - 531768 Scrip Code:- POLYM
Slide 2: Investor Presentation Q3 & 9M FY26 Results
Investor Presentation Poly Medicure Ltd. Q3 & 9M FY26 Results 05th Feb 2026
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Poly Medicure Limited (the "Company"), content of which was compiled from sources believed to be reliable for informational purposes only and are based on information regarding the Company and the economic, regulatory, market and other conditions as
Slide 4: Consolidated Performance Summary Q3 FY26 & 9M FY26
Consolidated Performance Summary Q3 FY26 & 9M FY26 Figs in Rs. Crs unless specified Margin,% Revenue Operating EBITDA1 PAT2 26.8% 24.2% 27.4% 25.8% 27.4% 19.2% 13.6% 19.1% 17.7% 19.1% 493.7 345.3 119.4 255.7 1,340.7 118.9 336.3 91.8 85.2 246.8 443.9 70.8 424.2 116.1 1,229.0 Q2 FY26 Q3 FY26 Q3 FY25 9
Slide 5: Key Updates
Key Updates • Clinical study on RisoR stent in progress, 200+ patients enrolled across centers in India Key Business • Received regulatory approval from DCGI for Intravenous Lithotripsy System (IVL) and Drug Eluting Balloon (DEB) Updates • Deepening SARATHII Program: AI led interactive training modu
Slide 6: Brief Overview of Impact of India US Trade Deal
Brief Overview of Impact of India US Trade Deal US India Trade Deal Impact on Medtech Sector ❑ Price competitiveness in the U.S. market U.S. duty cut from 50% to ~18% makes Indian medtech—especially disposables—significantly more cost- competitive than Chinese imports. ❑ Export expansion potential U
Slide 7: Brief Overview of Impact of India EU Trade Deal
Brief Overview of Impact of India EU Trade Deal India EU Trade Deal Impact on Medtech Sector ❑ Huge Market Access Agreement opens access to the EU’s ~$572 billion pharma and medical devices market — one of the largest and most sophisticated in the world ❑ Supply-Chain Integration & Resilience Deal c
Slide 8: Brief Overview of Impact of Budget 2026
Brief Overview of Impact of Budget 2026 Budget 2026 Impact on Medtech Sector ❑ Bigger Healthcare & Innovation Budget Health sector allocation was increased significantly to INR 105,503 Crores, showing strong government focus on health and allied technologies ❑ Focus on Domestic Capabilities Biopharm
Slide 9: Agenda: Financial Performance Analysis
Agenda Financial Performance Analysis 8
Slide 10: Standalone Financial Performance Summary
Standalone Financial Performance Summary Figs in Rs. Cr. unless specified YoY Growth QoQ Growth Particulars Q3 FY 26 Q3 FY 25 Q2 FY 26 9M FY 26 9M FY 25 YoY Growth % % % Revenue from Operations 418.9 410.9 1.9% 416.5 0.6% 1219.4 1180.8 3.3% Cost of Good Sold 134.5 140.2 (4.1%) 126.1 6.7% 382.6 387.9
Slide 11: Consolidated Financial Performance Summary
Consolidated Financial Performance Summary Figs in Rs. Cr. unless specified YoY Growth QoQ Growth Particulars Q3 FY 26 Q3 FY 25 Q2 FY 26 9M FY 26 9M FY 25 YoY Growth % % % Revenue from Operations 493.7 424.2 16.4% 443.9 11.2% 1340.7 1229.0 9.1% Cost of Good Sold 155.8 146.5 6.3% 135.7 14.8% 418.6 40
Slide 12: Consolidated Sales Performance Analysis
Consolidated Sales Performance Analysis Figs in Rs. Crs unless specified YoY QoQ YoY Particulars Q3 FY 26 Q3 FY 25 Q2 FY 26 9M FY 26 9M FY 25 Growth % Growth % Growth % Domestic 146.6 126.1 16.2% 140.9 4.0% 413.0 351.3 17.6% International 342.8 294.1 16.6% 300.3 14.1% 918.1 868.0 5.8% Other Operatin
Slide 13: Segment Wise Sales Performance Analysis
Segment Wise Sales Performance Analysis Figs in Rs. Crs unless specified YoY YoY QoQ Particulars Q3 FY 26 Q3 FY 25 Q2 FY 26 9M FY 26 9M FY 25 Growth Growth % Growth % % Infusion Therapy 274.3 261.1 5.0% 273.5 0.3% 799.7 798.1 0.2% Renal 44.8 38.9 15.1% 44.2 1.3% 132.5 106.2 24.7% Others 174.6 124.1
Slide 14: Return Ratios
Return Ratios ROCE ROE * 23% 23% 19% 18%* 19% 18%** 15% 14%** FY 23 FY 24 FY 25 DEC'25 FY 23 FY 24 FY 25 DEC'25 * EBIT excludes treasury income from QIP funds, acquisition costs, and Labour Code expenses, & is calculated on 12 months annualized basis 13
Slide 15: Shareholding Pattern as on 31st Dec 2025
Shareholding Pattern as on 31st Dec 2025 Key Shareholders % Shareholding Retail Investors Promoters 62.4% FPIs 9.4% Bodies Corporate 12.1% 2.2% DIIs 13.8% Others 0.03% Others 14.4% Alternate Investment Funds 2.6% Insurance Companies 3.1% Foreign Portfolio Investors 9.4% Promoters & Promoter Group 62
Slide 16: Thank You
Thank You For any investor related queries reach us at: aayur.verma@polymedicure.com 15